339 related articles for article (PubMed ID: 29477102)
1. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
[TBL] [Abstract][Full Text] [Related]
3. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
4. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
[TBL] [Abstract][Full Text] [Related]
5. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry.
Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Chuncharunee S; Niparuck P; Ekwattanakit S; Khuhapinant A; Norasetthada L; Nawarawong W; Makruasi N; Kanitsap N; Sirijerachai C; Chansung K; Wong P; Numbenjapon T; Prayongratana K; Suwanban T; Wongkhantee S; Praditsuktavorn P; Intragumtornchai T;
Ann Hematol; 2017 Jan; 96(1):57-64. PubMed ID: 27752821
[TBL] [Abstract][Full Text] [Related]
6. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
El-Galaly TC; Villa D; Michaelsen TY; Hutchings M; Mikhaeel NG; Savage KJ; Sehn LH; Barrington S; Hansen JW; Smith D; Rady K; Mylam KJ; Larsen TS; Holmberg S; Juul MB; Cordua S; Clausen MR; Jensen KB; Johnsen HE; Seymour JF; Connors JM; de Nully Brown P; Bøgsted M; Cheah CY
Eur J Cancer; 2017 Apr; 75():195-203. PubMed ID: 28237865
[TBL] [Abstract][Full Text] [Related]
7. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
[No Abstract] [Full Text] [Related]
8. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
[TBL] [Abstract][Full Text] [Related]
9. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
Perry C; Ben Barouch S; Goldschmidt N; Sarid N; Herishanu Y; Shvidel L; Bairey O; Lavi N; Horowitz N; Avigdor A; Lebel E; Sofer O; Ram R; Avivi I
Am J Hematol; 2019 Sep; 94(9):992-1001. PubMed ID: 31211434
[TBL] [Abstract][Full Text] [Related]
10. Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis.
Lang M; Feng Y; Meng X; Zhao J; Song Z; Qian Z; Qiu L; Zhou S; Liu X; Li L; Yang H; Song Y; Li W; Zhang H
Hematol Oncol; 2023 Apr; 41(2):239-247. PubMed ID: 34564882
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
[TBL] [Abstract][Full Text] [Related]
12. [Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma].
Yi S; Liu W; Lyu R; Li Z; Xu Y; Sui W; Huang W; Wang T; Deng S; Liu H; Fu M; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):546-50. PubMed ID: 24985182
[TBL] [Abstract][Full Text] [Related]
13. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse.
Villa D; Connors JM; Sehn LH; Gascoyne RD; Savage KJ
Haematologica; 2011 Jul; 96(7):1002-7. PubMed ID: 21486867
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
16. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
17. Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.
El-Galaly TC; Cheah CY; Hutchings M; Mikhaeel NG; Savage KJ; Sehn LH; Barrington S; Hansen JW; Poulsen MØ; Smith D; Rady K; Mylam KJ; Larsen TS; Holmberg S; Juul MB; Cordua S; Clausen MR; Jensen KB; Bøgsted M; Johnsen HE; Seymour JF; Connors JM; Brown PD; Villa D
Br J Haematol; 2016 Dec; 175(5):876-883. PubMed ID: 27681999
[TBL] [Abstract][Full Text] [Related]
18. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
Maciocia P; Badat M; Cheesman S; D'Sa S; Joshi R; Lambert J; Mohamedbhai S; Pule M; Linch D; Ardeshna K
Br J Haematol; 2016 Feb; 172(4):545-53. PubMed ID: 26684148
[TBL] [Abstract][Full Text] [Related]
19. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
20. Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma.
Garwood MJ; Hawkes EA; Churilov L; Chong G
Cancer Chemother Pharmacol; 2020 Jan; 85(1):133-140. PubMed ID: 31848681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
